Related Experiment Video
Updated: Mar 15, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Second-generation inhibitors of Bruton tyrosine kinase
Jingjing Wu1, Christina Liu2, Stella T Tsui3
1Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Abstract:
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported. The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib. This review summarizes the clinical development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Receptor Tyrosine Kinases
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Dipeptidyl Peptidase 4 Inhibitors
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

